A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody in Subjects With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 02 Apr 2018
At a glance
- Drugs JNJ 64007957 (Primary)
- Indications Haematological malignancies; Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors Janssen Research & Development
- 29 Mar 2018 Planned End Date changed from 1 Mar 2019 to 1 Oct 2019.
- 13 Jun 2017 Status changed from not yet recruiting to recruiting.
- 11 May 2017 New trial record